Related Experiment Video
Updated: Oct 28, 2025

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation
Published on: December 26, 2017
Intravenous immunoglobulin as adjuvant therapy for COVID-19: A case report and literature review
Carlos A Flores-Oria1, Emilio Saturno2, Supriya Ramanathan3
1Division of Pulmonology, Department of Pediatrics, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Abstract:
Severe acute respiratory syndrome coronavirus 2 has infected and caused the death of an alarming number of individuals worldwide. No specific treatment has been internationally standardized for coronavirus disease 2019 (COVID-19); however, in some cases, intravenous immunoglobulin (IVIG) has been used as adjuvant treatment in critically ill patients with COVID-19 pneumonia. We report a case of a 50-year-old man with severe COVID-19 pneumonia who received 5 days course of IVIG as adjuvant therapy. Invasive respiratory support was avoided. The patient had a successful recovery and was discharged without supplemental oxygen. A high dose of IVIG may improve survival in patients with severe COVID-19 pneumonia. In the current report, we reviewed literature on how IVIG use may improve the early stages of the disease.
More Related Videos
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Myocarditis III: Medical Management
Acute Pyelonephritis II: Diagnostic Studies and Management
Tonsillitis II: Management
Myocarditis IV: Nursing Management

